Search Results

Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced the presentation of new data, using Spinning Disk Intravital Microscopy (IVM), that provides real-time, in vivo visualization of the impact of α4β7 inhibition on lymphocyte trafficking in mouse gut-associated lymphoid tissues (GALT).

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2023.

Galt’s decision was based on lessons offered by the pandemic, along with research showing an increase in productivity and creativity brought about by the 4-day workweek model.

Galt Pharmaceuticals announced the acquisition of a specialty branded product from Fortovia Therapeutics.

The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.

Pharmaceutical innovator Galt Pharmaceuticals announced a new drug approval to offer a non-opioid, non-controlled, non-addictive alternative for healthcare providers to manage patients suffering from pain. On July 8, 2020 the U.S. Food and Drug Administration approved the company’s Supplemental Abbreviated New Drug Application for Orphengesic Forte, over two months ahead of the scheduled goal date. “This is a big win in the

Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today that Dr. Benjamin S. Carson, Sr. has been nominated to serve on the company’s board of directors.

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today announced it will participate in the 20th edition of the Discovery on Target meeting, the industry’s preeminent event on Novel Drug Targets and Technologies.